Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

ONTOLOGY REPORT - ANNOTATIONS


Term:EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor
go back to main search page
Accession:CHEBI:76729 term browser browse the term
Definition:An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-CH group of donors (EC 1.3.*.*).
Synonyms:related_synonym: EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitors;   EC 1.3.* inhibitor;   EC 1.3.* inhibitors;   inhibitor of oxidoreductase acting on CH-CH group of donor;   inhibitor of oxidoreductase acting on CH-CH group of donors;   inhibitors of oxidoreductase acting on CH-CH group of donor;   inhibitors of oxidoreductase acting on CH-CH group of donors;   oxidoreductase acting on donor CH-CH group inhibitor;   oxidoreductase acting on donor CH-CH group inhibitors


show annotations for term's descendants       view all columns           Sort by:
 





Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 23785
    role 23672
      biological role 23635
        biochemical role 22977
          enzyme inhibitor 21033
            EC 1.* (oxidoreductase) inhibitor 17931
              EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor 6339
                EC 1.3.1.* (oxidoreductase acting on donor CH-CH group, NAD(+) or NADP(+) as acceptor) inhibitor + 3268
                EC 1.3.3.* (oxidoreductase acting on donor CH-CH group, oxygen as acceptor) inhibitor + 484
                EC 1.3.5.* (oxidoreductase acting on CH-CH of donor with a quinone or related compound as acceptor) inhibitor + 51
                EC 1.3.98.* (oxidoreductase acting on donor CH-CH group, with other, known, acceptors) inhibitor + 2831
                EC 1.3.99.* (oxidoreductase acting on donor CH-CH group, with other acceptors) inhibitor + 1046
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.